Cassava Sciences (SAVA) Stock Crashes After Alzheimer’s Drug Fails in Phase 3 Testing

Cassava Sciences’ stock (SAVA) experienced a catastrophic drop on Monday, losing over three-quarters of its value. This collapse followed the failure of the company’s Alzheimer’s treatment, simufilam, in a critical Phase 3 trial. The trial evaluated simufilam’s efficacy in patients with mild-to-moderate Alzheimer’s disease. After a year of treatment, the drug failed to demonstrate a…

Read More